Although immunotherapy has been a game-changer for several cancers, its success in ovarian and other tumors remains quite limited. New nanoparticles developed through a Marble Center for Cancer Nanomedicine collaboration between the Hammond and former Irvine labs elicit a better response by delivering an immune-stimulating molecule called IL-12 directly to ovarian tumors. In a Nature Materials study, the team paired the nanoparticles with checkpoint inhibitor immunotherapies in a combination that eliminated metastatic tumors in more than 80 percent of mice, even in highly resistant models. The treatment also established immune memory, enabling mice to clear cancer cells when reintroduced several months later. Pursuing translational development, the researchers are working to launch a new company.